Impax Asset Management Group plc Boosts Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Impax Asset Management Group plc lifted its position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 81.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 470,603 shares of the company's stock after purchasing an additional 210,576 shares during the period. Impax Asset Management Group plc owned about 1.02% of Pacira BioSciences worth $7,083,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Jane Street Group LLC boosted its holdings in shares of Pacira BioSciences by 1,780.2% during the 1st quarter. Jane Street Group LLC now owns 187,531 shares of the company's stock valued at $5,480,000 after purchasing an additional 177,557 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Pacira BioSciences by 12.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,828,065 shares of the company's stock valued at $52,300,000 after acquiring an additional 198,936 shares during the last quarter. Legato Capital Management LLC increased its stake in Pacira BioSciences by 74.0% during the second quarter. Legato Capital Management LLC now owns 52,913 shares of the company's stock worth $1,514,000 after acquiring an additional 22,497 shares during the last quarter. WINTON GROUP Ltd bought a new stake in Pacira BioSciences in the second quarter worth $2,726,000. Finally, QRG Capital Management Inc. lifted its stake in Pacira BioSciences by 42.0% in the first quarter. QRG Capital Management Inc. now owns 22,708 shares of the company's stock worth $664,000 after purchasing an additional 6,721 shares during the last quarter. 99.73% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. Royal Bank of Canada raised their target price on shares of Pacira BioSciences from $15.00 to $16.00 and gave the company a "sector perform" rating in a research report on Thursday, November 7th. Piper Sandler lowered shares of Pacira BioSciences from an "overweight" rating to a "neutral" rating and reduced their price target for the stock from $42.00 to $11.00 in a research report on Monday, August 12th. Jefferies Financial Group lifted their price target on Pacira BioSciences from $15.00 to $18.00 and gave the company a "buy" rating in a research report on Tuesday, September 24th. Needham & Company LLC reissued a "buy" rating and issued a $22.00 price target on shares of Pacira BioSciences in a report on Friday, November 8th. Finally, JPMorgan Chase & Co. reissued an "underweight" rating and issued a $10.00 price objective (down from $45.00) on shares of Pacira BioSciences in a research note on Monday, August 12th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, Pacira BioSciences has a consensus rating of "Hold" and an average target price of $23.50.

Pacira BioSciences Stock Up 1.4 %

Shares of Pacira BioSciences stock traded up $0.23 on Friday, reaching $16.60. 780,465 shares of the company were exchanged, compared to its average volume of 857,121. The stock's 50 day moving average price is $15.81 and its 200-day moving average price is $20.68. The company has a market cap of $766.42 million, a P/E ratio of -8.18 and a beta of 0.82. Pacira BioSciences, Inc. has a 1-year low of $11.16 and a 1-year high of $35.95. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.